US Stock MarketDetailed Quotes
ITOS ITeos Therapeutics
- 7.420
- +0.200+2.77%
Close Dec 20 16:00 ET
- 7.450
- +0.030+0.41%
Post 19:29 ET
271.08MMarket Cap-2.36P/E (TTM)
7.510High7.090Low2.44MVolume7.170Open7.220Pre Close17.96MTurnover8.68%Turnover RatioLossP/E (Static)36.53MShares18.75052wk High0.43P/B208.84MFloat Cap7.09052wk Low--Dividend TTM28.15MShs Float52.430Historical High--Div YieldTTM5.82%Amplitude7.090Historical Low7.346Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
ITeos Therapeutics Stock Forum
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Thursday, 12th December at 8:55 am
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts
- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrat...
$ITeos Therapeutics (ITOS.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Pearson (PSO.US)$
$UnitedHealth (UNH.US)$
$Option Care Health (OPCH.US)$
$Procter & Gamble (PG.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Datadog (DDOG.US)$
$Pearson (PSO.US)$
$Procter & Gamble (PG.US)$
$Option Care Health (OPCH.US)$
$UnitedHealth (UNH.US)$
No comment yet